Article
Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.
Molecular psychiatry - 1 Oct 2021
DeMichele-Sweet Mary Ann A, Klei Lambertus, Creese Byron, Harwood Janet C, Weamer Elise A, McClain Lora, Sims Rebecca, Hernandez Isabel, Moreno-Grau Sonia, Tárraga Lluís, Boada Mercè, Alarcón-Martín Emilio, Valero Sergi, Liu Yushi, Hooli Basavaraj, Aarsland Dag, Selbaek Geir, Bergh Sverre, Rongve Arvid, Saltvedt Ingvild, Skjellegrind Håvard K, Engdahl Bo, Stordal Eystein, Andreassen Ole A, Djurovic Srdjan, Athanasiu Lavinia, Seripa Davide, Borroni Barbara, Albani Diego, Forloni Gianluigi, Mecocci Patrizia, Serretti Alessandro, De Ronchi Diana, Politis Antonis, Williams Julie, Mayeux Richard, Foroud Tatiana, Ruiz Agustin, Ballard Clive, Holmans Peter, Lopez Oscar L, Kamboh M Ilyas, Devlin Bernie, Sweet Robert A
Abstract excerpt
Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD with psychosis, AD + P). AD + P affects ~50% of individuals with AD, identifies a subgroup with poor outcomes, and is associated with a greater degree of cognitive impairment and depressive symptoms, compared to subjects without psychosis (AD - P). Although the estimated heritability of AD + P is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.